MCK Mckesson Dashboard

Risks

• We experience costly and disruptive legal disputes.
• We might experience losses not covered by insurance.
• We experience costly legal disputes, government actions and adverse publicity regarding our role in distributing controlled substances such as opioids.
• We might experience increased costs to distribute controlled substances such as opioids.
• We are subject to extensive, complex and challenging healthcare and other laws.
• We are subject to extensive and frequently changing local, state and federal laws and regulations relating to healthcare fraud, waste and abuse.
• We might lose our ability to purchase, compound, store or distribute pharmaceuticals and controlled substances.
• Pedigree tracking laws increase our compliance burden and our pharmaceutical distribution costs.
• Privacy and data protection laws increase our compliance burden.
• Anti-bribery and anti-corruption laws increase our compliance burden.
• We might record significant charges from impairment to goodwill, intangibles and other assets or investments.
• We experience cybersecurity incidents and might experience significant computer system compromises or data breaches.
• We might experience significant problems with information systems or networks.
• Our products or services might not conform to specifications or perform as we intend.
• We might be impeded in providing customers online services and data access.
• We might not realize expected benefits from business process initiatives.
• We might be unable to successfully complete or integrate acquisitions or other business combinations.
• We might be adversely impacted by delays or other difficulties with divestitures.
• We might not realize the expected tax treatment from our split-off of Change Healthcare.
• We might be adversely impacted by outsourcing or similar third-party relationships.
• We may be unsuccessful in retail pharmacy operations or maintaining profitability.
• We might be harmed by large customer purchase reductions, payment defaults or contract non-renewal.
• Our contracts with government entities involve future funding and compliance risks.
• We might be harmed by changes in our relationships or contracts with suppliers.
• We might infringe intellectual property rights or our intellectual property protections might be inadequate.
• We might be unable to successfully recruit and retain qualified employees.
• We might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models.
• We might be adversely impacted by competition and industry consolidation.
• We might be adversely impacted by changes or disruptions in product supply.
• We might be adversely impacted as a result of our distribution of generic pharmaceuticals.
• We might be adversely impacted by an economic slowdown or recession.
• Disruption or other changes in capital and credit markets might impede access to credit and increase borrowing costs for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers.
• We may have difficulties in sourcing or selling products due to a variety of causes.
• We might be adversely impacted by tax legislation or challenges to our tax positions.
• We might be adversely impacted by the Brexit withdrawal of the United Kingdom from the European Union.
• We might be adversely impacted by fluctuations in foreign currency exchange rates.
• We might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events and other catastrophic events.
• We might be adversely impacted by changes in accounting standards.